Automation for higher throughput in protein expression: visions, facts and fictions

Por Geisse Sabine, Schmitz Rita, Henke Mario, Rolvering Catherine, Barys Louise, Pouliquen Yann, Schlaeppi Jean, Mahnke Marion, Kolbinger Frank
Publicado em 2006-10-01

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

Por Breuleux, Madlaina, Klopfenstein, Matthieu, Stephan, Christine, Doughty, Cheryl A., Barys, Louise, Maira, Saveur-Michel, Kwiatkowski, David, Lane, Heidi A.
Publicado em 2009

The Tyrosine Phosphatase PTPN14 Is a Negative Regulator of YAP Activity

Por Michaloglou, Chrysiis, Lehmann, Waltraut, Martin, Typhaine, Delaunay, Clara, Hueber, Andreas, Barys, Louise, Niu, Honglin, Billy, Eric, Wartmann, Markus, Ito, Moriko, Wilson, Christopher J., Digan, Mary Ellen, Bauer, Andreas, Voshol, Hans, Christofori, Gerhard, Sellers, William R., Hofmann, Francesco, Schmelzle, Tobias
Publicado em 2013

Inhibition of wild-type p53-expressing AML by novel small molecule HDM2 inhibitor, CGM097

Por Weisberg, Ellen, Halilovic, Ensar, Cooke, Vesselina G., Nonami, Atsushi, Ren, Tao, Sanda, Takaomi, Simkin, Irene, Yuan, Jing, Antonakos, Brandon, Barys, Louise, Ito, Moriko, Stone, Richard, Galinsky, Ilene, Cowens, Kristen, Nelson, Erik, Sattler, Martin, Jeay, Sebastien, Wuerthner, Jens U., McDonough, Sean M., Wiesmann, Marion, Griffin, James D.
Publicado no Mol Cancer Ther (2015)

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf(−/−) mouse model

Por Chapeau, Emilie A., Gembarska, Agnieszka, Durand, Eric Y., Mandon, Emeline, Estadieu, Claire, Romanet, Vincent, Wiesmann, Marion, Tiedt, Ralph, Lehar, Joseph, de Weck, Antoine, Rad, Roland, Barys, Louise, Jeay, Sebastien, Ferretti, Stephane, Kauffmann, Audrey, Sutter, Esther, Grevot, Armelle, Moulin, Pierre, Murakami, Masato, Sellers, William R., Hofmann, Francesco, Jensen, Michael Rugaard
Publicado no Proc Natl Acad Sci U S A (2017)

Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma

Por Goyal, Lipika, Saha, Supriya K., Liu, Leah Y., Siravegna, Giulia, Leshchiner, Ignaty, Ahronian, Leanne G., Lennerz, Jochen K., Vu, Phuong, Deshpande, Vikram, Kambadakone, Avinash, Mussolin, Benedetta, Reyes, Stephanie, Henderson, Laura, Sun, Jiaoyuan Elisabeth, Van Seventer, Emily E., Gurski, Joseph M., Baltschukat, Sabrina, Schacher-Engstler, Barbara, Barys, Louise, Stamm, Christelle, Furet, Pascal, Ryan, David P., Stone, James R., Iafrate, A. John, Getz, Gad, Porta, Diana Graus, Tiedt, Ralph, Bardelli, Alberto, Juric, Dejan, Corcoran, Ryan B., Bardeesy, Nabeel, Zhu, Andrew X.
Publicado no Cancer Discov (2016)